glp-1 news today september 29 2025 ISPOR 2025: Exploring reasons for discontinuation GLP-1 receptor agonists are increasingly

10.1126/science.1094637

doi: 10.1084/jem.169.1.291 130 de SousaEBDos Santos JuniorGCAguiarRPda Costa SartoreRde OliveiraACLAlmeidaFCLet al

The number of injections will be in proportion to the size of the area being treated and the number of affected veins

Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that triggers GH release through a separate pathway, without significantly affecting cortisol or other hormones in research models

Over 68 weeks, participants on CagriSema lost an average of 22.7 per cent of body weight when measured on the basis that all stayed on treatment, against 2.3 per cent for placebo